Du är här

2015-09-24

Novartis International AG: Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

Novartis International AG / Novartis appoints James E. Bradner, MD as
President of the Novartis Institutesfor BioMedical Research as Mark Fishman
retires . Processed and transmitted by NASDAQ OMX Corporate Solutions.The
issuer is solely responsible for the content of this announcement.
* New leader to continue to drive long-term innovation in Novartis research
in wide range of therapeutic areas

Basel, September 24, 2015
-
Novartis announced today that Dr. James (Jay) E. Bradner, physician-scientist
from Dana-Farber Cancer Institute and Harvard Medical School, has been
appointed President of the Novartis Institutes for BioMedical Research (NIBR)
and a member of the Executive Committee of Novartis, effective March 1, 2016.

Dr. Bradner succeeds Mark C. Fishman, M.D., who will reach his contractual
retirement age in March 2016 after a distinguished 13-year career at Novartis
as the leader of the company's drug discovery and early clinical development
efforts.

"Mark has done an outstanding job leading NIBR, and he will be missed. He
redefined research at Novartis - recruiting top scientists and clinicians
from around the world, putting patient need and disciplined science at the
center of our strategy, which has filled our pipeline with new medicines,"
said Joseph Jimenez, CEO of Novartis.

"I am confident that Jay will continue this track record of success. He is an
accomplished scientist whose discoveries in the area of chemical biology have
revealed novel approaches for treating cancer and other illnesses. He is
also an entrepreneur who has been the driving scientific force behind several
biotech start-ups. His experience and perspectives make him a great fit to
further develop our internal research capabilities, as well as expand our
external collaboration efforts with biotech companies and academic
institutions."

Dr. Bradner will be based at NIBR's global headquarters in Cambridge,
Massachusetts and report to Joseph Jimenez, Chief Executive Officer of
Novartis. He will join Novartis on January 1, 2016 to work alongside Dr.
Fishman and the NIBR leadership team to ensure a smooth transition.

Dr. Bradner is on the faculty of Harvard Medical School in the Department of
Medical Oncology at the Dana-Farber Cancer Institute. He is a graduate of
Harvard College and the University of Chicago Medical School. He did his
residency in medicine at the Brigham&Women's Hospital, and fellowship in
Medical Oncology and Hematology at the Dana-Farber Cancer Institute, where he
has been on the faculty since 2005. Dr. Bradner has co-authored more than 130
scientific publications and 30 United States Patent applications.

Disclaimer

The foregoing release contains forward-looking statements that can be
identified by words such as "to continue," "long-term," "effective," "will,"
"confident," "to further develop . as well as expand," "to ensure," or
similar terms, or by express or implied discussions regarding the potential
impact of Dr. Fishman's retirement and of Dr. Bradner's leadership on
Novartis. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations
of management regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that Dr. Fishman's
retirement and Dr. Bradner's appointment will have any particular impact on
NIBR or Novartis. In particular, management's expectations could be affected
by, among other things, the uncertainties inherent in research and
development, including unexpected research or clinical trial results and
additional analysis of existing data; unexpected regulatory actions or delays
or government regulation generally; the company's ability to obtain or
maintain proprietary intellectual property protection; general economic and
industry conditions; global trends toward health care cost containment,
including ongoing pricing pressures; unexpected manufacturing issues, and
other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing
the information in this press release as of this date and does not undertake
any obligation to update any forward-looking statements contained in this
press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2014, the Group
achieved net sales of USD 58.0 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 120,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis
athttp://twitter.com/novartis.

# # #

Novartis Media Relations

------------------------------------------------------------------
| Central media line : |
|+41 61 324 2200 |
| Liz Power Dermot Doherty |
| |
|Novartis Global Media Relations Novartis Global Media Relations |
|1 212 830 2466 (direct) +41 61 696 8653 (direct) |
|1 617 583 3015 (mobile) +41 79 536 9755 (mobile) |
|elizabeth.power@novartis.com dermot.doherty@novartis.com |
------------------------------------------------------------------
Jeffrey Lockwood

Novartis Institutes for BioMedical Research Communications
1 617 871 7026 (direct)
1 617 510 6997 (mobile)
jeffrey.lockwood@novartis.com

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please
contact:journalisthelp@thenewsmarket.com.

Novartis Investor Relations

----------------------------------------------------------------------------------
| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
----------------------------------------------------------------------------------

Media release (PDF)
http://hugin.info/134323/R/1954201/711167.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire

HUG#1954201

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.